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Abstract Although sentinel lymph node mapping has been widely implemented in 
gynecological malignancies in order to minimize the number of unnecessary lymph node 
dissections and to diminish postoperative morbidity rate, little is known about ovarian 
cancer sentinel lymph node mapping. This article presents a literature review regarding 
the effectiveness, safety and benefits of this method. 
Sentinel lymph node detection in early stage ovarian cancer seems to be a safe and 
effective method, able to minimize the rate of patients submitted to unnecessary lymph 
node dissection. The second goal of the procedure, to minimize the risk of missing 
involved lymph nodes, seems also to have been achieved, most studies reporting a very 
small number of cases diagnosed with positive non-sentinel lymph nodes.  
Considering all these data we can note that this procedure is not yet included as part 
of the standard therapeutic protocol, so that further studies would be necessary to include 
it as a common therapeutic approach in the case of patients with early stage ovarian 
cancer.   
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Highlights ✓ In early stage ovarian cancer, the sentinel lymph node detection seems to be a safe and 
effective method, able to limit unnecessary lymph node dissection. 
✓ The risk of not identifying invaded lymph nodes is relatively low, most studies reporting 
a very small number of cases diagnosed with positive non-sentinel lymph nodes.    
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Introduction 
Ovarian cancer is one of the most common 
malignancies and the leading cause of death from 
gynecological cancers, especially due to the fact that 
most cases are diagnosed in advanced stages of disease 
when disseminated lesions are already present. 
However, up to one third of ovarian cancer patients are 
diagnosed in early stages of disease, with improved 
chances of long-term survival. Moreover, such cases 
present a low incidence of lymph node involvement; 
therefore, these women would not benefit should routine 
lymph node dissection be performed, while 
simultaneously being exposed to a higher risk of 
perioperative complications. In such patients, 
performing an extended lymph node dissection is 
usually associated with a longer operative time, a longer 
hospital stay, a larger amount of blood loss, and an 
increased risk of developing lymphoceles or chronic 
lower limb lymphedema without improving the survival 
rate (1-5). 
Discussions 
The pattern of ovarian lymphatic drainage     
Studies regarding the pattern of lymphatic drainage 
of the ovaries demonstrated that in up to 84% of cases 
an isolated para-aortic drainage is expected, in 8% of 
cases isolated pelvic drainage is seen, while the 
remaining 8% of patients will experience both pelvic 
and para-aortic drainage (6). The development of para-
aortic and para-caval metastases is explained by the 
dissemination through the lymph vessels accompanying 
the ovarian artery and vein, in the suspensory ligament 
while the appearance of pelvic metastases is explained 
by the tumor cell migration along the proper ovarian 
ligament to the para-uterine vessels, the broad 
ligaments, and further toward the iliac vessels (3, 4, 7).  
Principles of sentinel lymph node detection after 
injecting the tracer in the ovarian area. 
The principle of sentinel lymph node mapping has 
been initially studied in cases with normal ovaries or in 
patients submitted to surgery for ovarian cysts. The 
procedure consists of radiotracer injection in the 
mesovarian tissues; sentinel lymph nodes are detected at 
a mean interval of 4-6 hours after injection by 
performing a lymphoscintigraphy and are mainly 
detected in the para-aortic or pelvic and para-aortic 
areas. Interestingly, in post-menopausal women, 
isolated para-aortic drainage was seen more frequently 
when compared with pre-menopausal subjects (6, 8).  
As for the chosen tracer, it must be a small particle 
size in order to provide rapid dissemination from the site 
of injection into the lymphatic system and therefore, a 
rapid accumulation in the sentinel lymph nodes (9, 10). 
Association between radioactive tracer and blue dye is 
also known under the generic name of dual mapping 
method and seems to decrease the rate of failure or false 
negative sentinel node detection (5, 11). However, the 
blue dye might disappear from the lymph nodes if a 
longer period of time passes between injection and 
exploration; moreover, certain authors have reported a 
higher risk of adverse reactions after blue dye injection, 
such as allergic reactions, including anaphylactic shock 
(12, 13).  
Regarding the site of injection, subcortical or sub-
peritoneal, intraligamentary injection has been 
proposed; while subcortical injection seems to be 
associated with a lower detection rates as well as with 
the risk of tumor puncture, the sub-peritoneal, 
intraligamentary route seems safer and more effective 
(5).  
Due to the high risk of tumoral dissemination if 
ovarian cortex is injected, certain authors contraindicate 
this maneuver, routinely recommending intra-
ligamentary, sub-peritoneal injections. The first study 
which evaluated the injection of the ovarian ligaments 
was conducted by Kleppe et al. in Maastricht University 
Medical Center, The Netherlands, and was published in 
2014 (12). The authors included 21 patients in whom 
blue dye and radioactive isotope were injected on the 
ventral and dorsal side of the proper and suspensory 
ligaments of the ovary, underneath the peritoneal shield. 
Fifteen minutes after injection, the ovarian mass was 
resected and sent to frozen section, while the lymph 
node regions were examined by using an 11-mm straight 
gamma probe; any lesion presenting a radiation signal 
of at least 10-fold higher than background radiation was 
considered positive. In the meantime, the main 
lymphatic areas were classified as upper or lower para-
aortic regions (separated by the origin of the inferior 
mesenteric artery), upper and lower paracaval regions, 
and right or left pelvic regions. After sending the 
adnexal masses for frozen section examination, seven 
cases proved to have a benign tumor, eight presented 
borderline tumors while the remaining six cases were 
diagnosed with epithelial ovarian cancer. After injecting 
the radioactive tracer, hot spots were present only in the 
para-aortic/para-caval region in 67% of cases, in the 
pelvic region only in 9% of cases, and in both para-
aortic/para-caval and pelvic regions in 24%, all but two 
of the 3 identified sentinel lymph nodes being located on 
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the ipsilateral side. Moreover, patients presenting left 
ovarian tumors reported the presence of sentinel lymph 
nodes between the inferior mesenteric artery and the left 
renal vein while patients diagnosed with right ovarian 
masses were mainly located in the close proximity of the 
origin of the inferior mesenteric artery.  
In all six cases in which para-aortic sentinel lymph 
nodes were discovered, a high capitation of the 
radiotracer was identified by using the gamma probe 
while two of these six patients also associated a blue 
staining of the sentinel lymph nodes. However, the 
reduced number of sentinel lymph nodes which were 
identified by using the blue staining technique was 
explained by the longer period of time between blue dye 
injection and retroperitoneal space exploration. A total 
of 18 sentinel lymph nodes were retrieved; in one case 
in which four sentinel lymph nodes were retrieved, three 
of the four presented metastases.  
Therefore, the patient was submitted to a complete 
lymph node dissection, another positive, non-sentinel 
lymph node being discovered. In fact, this was the single 
case in which positive, metastatic sentinel lymph nodes 
were diagnosed; in all the other five cases none of the 
retrieved sentinel lymph nodes presented any tumoral 
involvement. When analyzing the radiation exposure to 
personnel, the mean exposure for the surgeon during 
three procedures was 0.06 mSv at the dominant hand 
and 0.17 mSv at the non-dominant hand. Therefore, the 
authors concluded that the method of intra-ligamentary 
injection of radiotracer or blue dye is a safe and effective 
method to correctly identify the sentinel lymph nodes in 
early stage ovarian cancer. Moreover, it seems that the 
exposure of personnel is minimal (12).  
The role of postoperative lymphoscintigraphy after 
performing a sentinel lymph node excision procedure 
Certain authors consider that performing a 
postoperative lymphoscintigraphy is the only method 
able to confirm the complete excision of all sentinel 
lymph nodes in patients with malignant lesions. 
Moreover, in patients with benign lesions, such 
imagistic studies can show the exact location of the 
sentinel lymph node and, therefore, can show the pattern 
of ovarian lymphatic drainage (5). 
The role of sentinel lymph node biopsy in early 
stage ovarian cancer 
Although the principles of sentinel lymph node 
mapping have been widely implemented in other 
gynecologic malignancies such as breast, cervical, 
endometrial, or vulvar cancer, data regarding ovarian 
cancer are rather scarce, only a few studies being 
conducted thus far. Given the estimated incidence of 
positive lymph node in early stage ovarian cancer 
ranging between 5-15%, sentinel node technique has 
been recently proposed for such cases in order to clearly 
identify which cases could benefit from an extended 
lymph node dissection and in which cases this procedure 
might be avoided in order to diminish the postoperative 
morbidity rate (14, 15).  
In their study, Hassanzadeh et al. included 35 
patients diagnosed with ovarian tumors (5). Sentinel 
lymph node mapping was provided by Tc-99m-phytate 
injection just after performing laparotomy; in the first 10 
cases the tracer was injected in the normal cortex of the 
ovary while in the remaining 25 cases the injection was 
performed in the utero-ovarian and suspensory 
ligaments, in close proximity to the affected ovary. In 
the meantime, in four cases belonging to the second 
group, patent blue dye was also injected at the same 
points as the radiotracer. Ten minutes after injection the 
adnexal mass was resected and was sent for frozen 
sectioning. Once the diagnosis of malignancy was 
established, the sentinel nodes were identified using a 
hand-held gamma probe in the para-aortic and pelvic 
areas. All lymph nodes with three times more count than 
baseline were considered as sentinel, were resected, and 
sent for histopathological study while the surgeon 
completed the lymph node dissection.  
In patients diagnosed with benign or borderline 
ovarian tumors, gamma probe was used to locate the hot 
areas. In the first day postoperatively, all patients were 
referred to the nuclear medicine service to submit to 
pelvic and abdominal lymphoscintigraphy. Among the 
10 cases in which injection was performed in the ovarian 
cortex, three had malignant lesions while the remaining 
seven proved to be benign. As for the identification of 
sentinel lymph nodes, this method was successfully 
performed in four cases (two cases with benign lesions 
and the other two with malignant tumors). Among the 
other 25 patients who were submitted to intra-
ligamentary, subperitoneal injections, the frozen 
sections revealed 11 malignant lesions, one borderline 
tumor, and 13 benign tumors; sentinel lymph node 
detection was possible in 21 cases (all cases with 
malignant tumors and in 10 cases with benign lesions).  
An important factor that influenced the possibility 
of detection of sentinel lymph nodes was the association 
with ovarian torsion, in none of the four cases presenting 
adnexal torsion sentinel lymph node detection being 
impossible. This fact is mainly explained through the 
interruption of the lymphatic flow once the torsion has 
occurred. As for the areas in which the sentinel lymph 
nodes were found, in 12 cases they were reported only 
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in the para-aortic area (all patients presenting benign 
lesions), in the other nine cases they were identified in 
both pelvic and para-aortic areas, while in two cases 
(both with malignant pathology) sentinel lymph nodes 
were found in the pelvic area. In all cases in which blue 
dye injection was associated, all sentinel lymph nodes 
(detected by gamma probe usage) were colored in blue. 
Moreover, three patients with malignant lesions 
presented involved lymph nodes on pathology, all of 
them being previously diagnosed as sentinel lymph 
nodes; therefore, the sensitivity rate was 100%, no false 
negative result being encountered. The first patient who 
was diagnosed with a positive sentinel lymph node was 
a 60-year-old who was submitted to surgery for bilateral 
ovarian tumors, the frozen and histopathological studies 
demonstrating the presence of a papillary serous 
adenocarcinoma. After injecting the tracer, three hot 
sentinel nodes were identified (two among the para-
aortic lymph nodes and one in the obturatory fossa), two 
of the three nodes being finally involved. Although 
complete pelvic and para-aortic lymph node dissection 
were associated, no other positive lymph node was 
found.  
The second case was a 35-year-old patient 
diagnosed with bilateral ovarian tumors which proved to 
be a papillary serous adenocarcinoma; two hot and blue 
sentinel lymph nodes were seen in the para-aortic area, 
one of them being pathologically involved. Although 
surgery was completed by performing a total 
hysterectomy with bilateral adnexectomy, pelvic and 
para-aortic lymph node dissection, no other positive 
lymph nodes were found. The third case was a 35-year-
old female woman diagnosed with bilateral papillary 
serous adenocarcinoma, two hot and blue sentinel lymph 
nodes being found in the para-aortic area. One of them 
proved to be histopathologically positive; in the 
meantime, after completing the procedure by 
performing a total hysterectomy with bilateral 
adnexectomy and pelvic and para-aortic lymph node 
dissection, another positive para-aortic non-sentinel 
lymph node was found. Moreover, in the second 
postoperative day, when performing the test 
lymphoscintigraphy, no remaining activity was seen 
either in pelvis or in the abdominal cavity in any of the 
three cases (5).  
More recently, identifying the sentinel lymph nodes 
by using indocyanine green (ICG) injection has been 
proposed in patients with gynecological malignancies. 
Preliminary reports demonstrated the safety and 
effectiveness of the method in patients with endometrial 
cancer, further evaluation in other gynecological 
malignancies including ovarian cancer being expected 
(16). One of the first reports regarding the feasibility of 
ICG technique in early stage ovarian cancer was 
reported this year by Isid and colleagues from Nantes 
Hospital, France. The authors reported the case of a 47-
year-old patient diagnosed with grade 3 endometroid 
ovarian cancer confined to the ovary after a laparoscopic 
right adnexectomy.  
Twenty days later the patient was submitted to a 
comprehensive surgical staging, so that the ICG 
injection was performed. The sites of injection were the 
uterine cervix—in order to identify any pelvic sentinel 
lymph node—and the right infundibulopelvic 
ligament—in order to identify any para-aortic lymph 
node. When inspecting the pelvic and para-aortic 
lymphatic areas by using a near infrared high intensity 
light source, one sentinel lymph node was identified in 
each hemipelvis and one in the supramesenteric infra-
renal area. Due to the experimental nature of the ICG 
technique in ovarian cancer, the authors decided to 
perform an extended lymph node dissection; however, 
none of the resected lymph nodes (sentinel or non-
sentinel lymph nodes) were involved (17). 
Conclusions 
Sentinel lymph node detection in early stage 
ovarian cancer seems to be a safe and effective method 
to minimize the rate of patients submitted to 
unnecessary lymph node dissection. In the meantime, 
the second goal of the procedure, to minimize the risk of 
missing involved lymph nodes, seems also to have been 
achieved, most studies reporting a very small number of 
cases diagnosed with positive non-sentinel lymph nodes. 
However, further studies are necessary in order to 
standardize this method as part of the therapeutic 
protocol of these patients. 
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